

*In cutaneous T-cell lymphoma (CTCL) subtypes
mycosis fungoides (MF) and Sézary syndrome (SS)...*

Make progress. Delay progression.

**Progression-free survival (PFS) more than doubled versus
vorinostat^a in the largest Phase 3 trial (MAVORIC) of systemic MF and SS therapy.^{1,2}**

POTELIGEO® (mogamulizumab) is indicated in the EU for the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.²

For full prescribing information refer to the Summary of Product Characteristics, available [here](#)

^a Vorinostat is a USA FDA-licensed existing treatment for MF and SS and is currently unlicensed in the EU. All references to vorinostat within this document are included only for the purposes of accurately conveying details of the MAVORIC trial and are not intended to promote the use of vorinostat.

1. Kim YH, Bagot M, Pinter-Brown L, et al. *Lancet Oncol.* 2018;19(9):1192–1204.

2. POTELIGEO® Summary of Product Characteristics (SmPC). Published: 28 January 2019. Updated: 20 August 2021. Accessed: September 2021.

**Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email medinfo@kyowakirin.com**

POTELIGEO® is a registered trademark of the Kyowa Kirin Group. © 2021 Kyowa Kirin International plc. All rights reserved.
KKI/INT/MOG/0440 Date of preparation: October 2021.

